Celixir LTD - Formerly Known as Cell Therapy Ltd

Celixir (formerly known as Cell Therapy Ltd.) is a private British regenerative medicine company that discovers and develops life-saving and life-altering regenerative medicines for patients with the greatest medical need.

Celixir, founded in 2009, is made up of a world-class team of scientists and biopharmaceutical executives, led by Nobel Laureate Professor Sir Martin Evans and former Roche Global Head of Emerging Technologies, Ajan Reginald.

celixir cell therapy


Celixir’s unique platform technology allows us to adopt an ‘off-the-shelf’ approach to deliver regenerative medicines to patients.

Website : http://www.celixir.com

Headquarters : Cardiff, Wales
Year Founded : 2009
Company Type : Privately Held
Size : 11-50 employees
Specialties : regenerative medicine, cell therapies, cardiovascular medicine, cellular research, stem cells

Location: United Kingdom

Comments

Post a Comment

Popular posts from this blog

Celixir’s CEO discuss about his agreement with the Japanese firm to distribute its heart failure drug

Image
Just days after the Cardiff-based cell therapy company Cell Therapy Ltd (CTL) signed an agreement with Japan’s Daiichi Sankyo, providing them with the rights to its heart failure drug Heartcel, the company’s chief executive, Ajan Reginald , got interviewed by one of the leading dailies. Heartcel, an immune-modulator progenitor (iMP), can be considered as one of the allogeneic celixir stem cells therapy which posses the power to redevelop the human heart. The same therapy has confirmed two-year MACE-free survival for all the tested patients in the Phase II clinical trial studying myocardial regeneration. As per the agreement, Daiichi Sankyo will take care of the development, regulatory approval and marketing of Heartcel in the Japanese territory, while CTL will still holds the rights for the rest of the world. Mr. Ajan Reginald , the co-founder of CTL, quoted that the deals comes as a future step towards accomplishing the global mission of bringing company’s life-saving dru
Read more

Celixir and their Collaborative Partnerships with Global Firms to Further Promote Their Regenerative Medicines Worldwide

Image
Celixir is one of the most sought after UK firms which are involved in the design and development of life changing regenerative medicines while working towards common objectives with certain collaborative partnerships. With that said, let’s take a look at some of the most talked about collaborations which Celixir has secured with some of the most recognized firms and institutions in the past decade. DAIICHI SANKYO Celixir has given the license for carrying on the marketing and distributing responsibilities of their revolutionary cardiac regeneration medicine to Daiichi Sankyo on May 2016. Going by the agreement, Daiichi Sankyo will take care for the development, regulatory and commercial activities for Celixir’s immune-modulatory progenitor cells across Japanese territory. Moreover, Celixir will still be responsible for the same operations within territories across rest of the world for Celixir stem cell therapy. INNOVATIVE CARDIOVASCULAR MEDICINES COLLABORATION Celixir has also for
Read more

Celixir announces US FDA approval of the IND application for cell therapy Heartcel

Image
Celixir announces US FDA approval of the IND application for cell therapy Heartcel FDA IND and UK MHRA CTA approval both achieved in H1 2018 Potentially pivotal heart failure trial of up to 250 patients in the UK and US Stratford-upon-Avon, UK, 08 June 2018  – Celixir, a privately owned company discovering and developing life-saving advanced therapies, announces that the US Food and Drug Administration (FDA) has approved its Investigational New Drug application (IND) for Heartcel its immuno-modulatory progenitor (iMP) cell therapy for the treatment of adult heart failure. Celixir announced in January the approval of a clinical trial application (CTA) from the UK’s Medicines and Healthcare products Regulatory Agency to initiate a potentially pivotal Phase II b human clinical trial with Heartcel The international trial will recruit up to 250 patients and the IND approval allows expansion to US clinical trial sites. Ajan Reginald, Chief Executive
Read more